iconiifl-logo-icon 1
IIFL

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

Government and Gennova negotiating a competitive price for mRNA vaccine

30 Jun 2022 , 01:26 PM

The Covid-19 vaccine from Gennova Biopharmaceuticals would be reasonably priced, according to the company, which acquired emergency use authorization (EUA) from India's medicines regulator on Wednesday. The first domestically produced mRNA Covid vaccination is offered by Gennova, a company based in Pune.

The creation of the vaccine had received government assistance. Government price negotiations are still going on, according to chief operating officer Samit Mehta.

"In terms of pricing, there is currently continuous conversation with the government on this subject. We will be considerably more competitive than our international competitors on this platform, I can guarantee with certainty, he added during a press conference.

Gennova has manufactured 7 million doses since receiving the manufacturing-at-risk permission. They have all been approved for distribution by the company's internal quality control and the government's nodal Central Drugs Laboratory at Kasauli in Himachal Pradesh, according to him. "So as in, we should be able to send this right away as the orders come through," he said.

Since the majority of people have already received both doses of the Covid vaccination, Mehta stated that the potential market for the vaccine would be for booster shots. The next step, according to him, would be to position the vaccine for use in youngsters.

Since the start of classes again, several youngsters have become ill, he claimed. Therefore, I believe that (vaccinating children) will be the right course of action. To export the novel vaccine, the business intends to take advantage of Emcure Pharmaceuticals' extensive global network.

Mehta reported that questions for Gennova had already come from Southeast Asia and Latin America. The records and the most recent update of the EUA in India have previously been submitted to the regulatory agency by a country in Latin America, he continued.

According to him, the parent business Emcure has operations in more than 70 nations. "The emergency use authorization has now been issued to the entire network," he continued, "so that any requests that may come in will be correctly routed."

Mehta added that a considerable sum had been spent on the creation of the vaccine. He said that the business had been developing an mRNA platform for more than four years.

Related Tags

  • Gennova GoI mRNA
sidebar mobile

BLOGS AND PERSONAL FINANCE

Images
28 Mar 2024   |   03:36 PM
Images
28 Mar 2024   |   03:01 PM
Images
28 Mar 2024   |   01:21 PM
Images
28 Mar 2024   |   01:02 PM
Read More
Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.